Drozitumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | DR5 |
| Identifiers | |
| CAS Number | 912628-39-8  |
| ATC code | none |
| UNII | SQ67484MA7  |
| Chemical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molecular mass | 143.1 kg/mol |
| (what is this?) (verify) |
|
Drozitumab is a human monoclonal antibody designed for the treatment of cancers.[1]
Drozitumab was developed by Genentech.
Adverse drug effects
Lua error in package.lua at line 80: module 'strict' not found.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles using small message boxes
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
